–
Leveraging the Company’s proprietary S1S3 bicistronic expression platform, M041 is co-expressed human NAGLU and S1S3, resulting in NAGLU
M6P –
–
With increased efficiency to phosphorylate lysosomal enzymes, M041 is a potential novel recombinant enzyme therapy for Sanfilippo B syndrome –
ST. LOUIS, MO, USA I July 28, 2021 IM6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced pre-clinical proof-of-concept data on M041 in a poster presentation by Patricia Dickson, M.D., Centennial Professor of Pediatrics and Chief, Division of Genetics and Genomic Medicine, Washington University of St. Louis, titled “
Hits: 233
DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone
HORSHAM, PA, USA I July 12, 2021 I The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX
FASPRO
® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. The approval follows the regulatory submission to the FDA in November 2020 and marks the sixth indication for DARZALEX
Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate | Vaccines pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.